GOVX News and Press, GeoVax Labs Inc. From 05/13/24

2024-05-13 17:35:36 ET Major earnings expected after the bell on Tuesday include: Oxford Lane Capital Corp. ( OXLC ) Capital Southwest Corporation ( CSWC ) Seadrill Limited ( SDRL ) Nu Holdings Ltd. ( NU ) Canoo ( GOEV ) Read the full articl...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA - ( NewMediaWire ) - May 07, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report first quarter...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

Presentation Made During the 24th Annual World Vaccine Congress   ATLANTA, GA - ( NewMediaWire ) - April 04, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced...

ATLANTA, GA  - ( NewMediaWire ) - March 28, 2024 -  GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-...

ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will presen...

ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36t...

GeoVax Labs (NASDAQ: GOVX) , is a clinical-stage biotech company committed to developing safe and effective vaccines and immunotherapies against cancers and infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy,  Gedeptin(...

Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA  - ( NewMediaWire ) - March 06, 2024 -  GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectio...